In December 2020, Aligos entered into an Exclusive License and Research Collaboration Agreement with Merck, known as MSD outside the United States and Canada, under which Merck and Aligos will apply Aligos’ oligonucleotide platform to discover, research, optimize and develop oligonucleotides directed against a NASH target and up to one additional target of interest in the cardiometabolic/fibrosis space.

Luxna Biotech


In December 2018, Aligos entered into an agreement with Luxna Biotech Co., Ltd. whereby Aligos acquired from Luxna an exclusive license to innovative modified nucleic acid technology coming out of Professor Satosh Obika’s lab at Osaka University targeting multiple genes in specific diseases.

KU Leuven


In July 2020, Aligos entered into a collaboration and license agreement with KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), and the Rega Institute for Medical Research, to develop a coronavirus protease inhibitor as a potential therapeutic candidate to address the COVID-19 pandemic (caused by SARS-CoV-2 infection) and other potential zoonotic coronavirus infections. Professor Johan Neyts, Ph.D. is the principal investigator at KU Leuven.

AM Chemicals


In January 2020, Aligos entered into a license and supply agreement with AM Chemicals, LLC, whereby Aligos acquired from AM Chemicals an exclusive right to the use of specific constructs for targeting therapeutics such as oligonucleotides to the liver.

Emory University


In June 2018, Aligos entered into an agreement with Emory University whereby Aligos acquired from Emory a license to technology with respect to a novel class of non-nucleoside class-II capsid assembly modulators. The underlying technology licensed by Aligos was invented and developed at Emory in the laboratory of Raymond Schinazi, PhD, DSc, FAASLD (Pediatrics) by Dr. Schinazi and his team including Sebastien Boucle, PhD (Pediatrics), Franck Amblard, PhD (Pediatrics), Ozkan Sari, PhD (Pediatrics) and Leda Bassit, PhD (Pediatrics).

Amoytop Biotech


In May 2023, Aligos entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. (“Amoytop”) for the use of Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.